ThermoGenesis Expands Commercial Access To Its Bioprocessing Equipment

Pixabay License | Source:  A_Different_Perspective , no changes made.
Advertisement

ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics, and a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, has announced that its AXP® II System for cord blood processing and PXP® System for point-of-care harvesting of highly enriched mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) from bone marrow, while significantly reducing red blood cells (RBCs), are now registered and available for sale in Thailand. Both systems are part of an advanced and clinically differentiated portfolio of cellular processing solutions aimed at supporting the development of cell-based therapeutics, including the emerging CAR-T market.

Incorporated in 2017, ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market.

Founded in 1986, headquartered in the Greater Sacramento Area, California, Cesca Therapeutics Inc. is a market leader in cell processing technologies and autologous cell therapies for regenerative medicine. It is affiliated with the Boyalife Group, headquartered in the Greater Shanghai Area, China.

The AXP® II System is a proprietary, automated system for the isolation, collection and storage of hematopoietic stem cell concentrates from cord blood. The PXP® laboratory equipment allows for the rapid, automated processing of autologous bone marrow-derived stem cells at the point of care, such as in surgical centers and clinics.

“Expanding our footprint into Southeast Asia is a logical next step, especially as research and development activities in the field of cell therapy are robust across Asia.” … “We look forward to supporting the needs of hospitals, clinics and GMP laboratory customers with our state-of-the-art and cost-effective cell-based therapy tools.” – Haihong Zhu, ThermoGenesis’ President

Sources

  1. https://www.prnewswire.com/news-releases/thermogenesis-axp-ii-and-pxp-systems-now-registered-and-available-in-thailand-300829515.html
  2. https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=529965508
  3. https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=35517
  4. https://www.boyalifegroup.com/contact-us/
Advertisement

David is a consultant/medical writer for a number of ongoing healthcare initiatives including for Athla LLC/ HealthLabs, a discovery automation company for Big Data leveraging Big Compute. He has a number of years experience in academic R&D and healthcare related projects including the fields of oncology and immunotherapy.